Abivax SA American Depositary Shares (ABVX)vsAlnylam Pharmaceuticals Inc (ALNY)
ABVX
Abivax SA American Depositary Shares
$124.33
+4.62%
HEALTHCARE · Cap: $10.83B
ALNY
Alnylam Pharmaceuticals Inc
$205.48
-28.31%
HEALTHCARE · Cap: $35.71B
Smart Verdict
WallStSmart Research — data-driven comparison
Alnylam Pharmaceuticals Inc generates 87033% more annual revenue ($4.29B vs $4.92M). ALNY leads profitability with a 12.6% profit margin vs 0.0%. ALNY earns a higher WallStSmart Score of 65/100 (B-).
ABVX
Avoid33
out of 100
Grade: F
ALNY
Strong Buy65
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for ABVX.
Margin of Safety
+86.2%
Fair Value
$2337.47
Current Price
$205.48
$2131.99 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 35.2% year-over-year
Growing faster than its price suggests
Every $100 of equity generates 54 in profit
Revenue surging 96.4% year-over-year
Strong operational efficiency at 23.0%
Areas to Watch
0.0% earnings growth
0.0% margin — thin
Weak financial health signals
Trading at 20.2x book value
0.0% earnings growth
Elevated debt levels
Premium valuation, high expectations priced in
Trading at 25.5x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : ABVX
The strongest argument for ABVX centers on Revenue Growth. Revenue growth of 35.2% demonstrates continued momentum.
Bull Case : ALNY
The strongest argument for ALNY centers on PEG Ratio, Return on Equity, Revenue Growth. Revenue growth of 96.4% demonstrates continued momentum. PEG of 0.49 suggests the stock is reasonably priced for its growth.
Bear Case : ABVX
The primary concerns for ABVX are EPS Growth, Profit Margin, Piotroski F-Score.
Bear Case : ALNY
The primary concerns for ALNY are EPS Growth, Debt/Equity, P/E Ratio. A P/E of 67.0x leaves little room for execution misses.
Key Dynamics to Monitor
ABVX profiles as a hypergrowth stock while ALNY is a growth play — different risk/reward profiles.
ALNY carries more volatility with a beta of 0.27 — expect wider price swings.
ALNY is growing revenue faster at 96.4% — sustainability is the question.
ALNY generates stronger free cash flow (49M), providing more financial flexibility.
Bottom Line
ALNY scores higher overall (65/100 vs 33/100) and 96.4% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Abivax SA American Depositary Shares
HEALTHCARE · BIOTECHNOLOGY · USA
Abivax SA is a clinical-stage biotechnology firm focused on pioneering immunotherapies for chronic inflammatory diseases and viral infections. Its lead candidate, ABX464, is in advanced clinical trials targeting ulcerative colitis, utilizing a novel approach that integrates antibody-mediated therapies with proprietary compounds. Backed by a robust pipeline and an experienced scientific team, Abivax is strategically positioned to meet substantial unmet medical needs, making it an attractive prospect for institutional investors aiming to engage with the growing immunotherapy landscape.
Alnylam Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?